MOUNTAIN VIEW, Calif., Nov. 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced the promotion of Peter Tam to president of VIVUS. In this position, Mr. Tam will lead and have overall responsibility for VIVUS' development and business functions, including corporate and product strategy, business development, clinical and preclinical development, regulatory affairs and chemistry, manufacturing and controls. Leland Wilson, formerly president and chief executive officer, will remain CEO of VIVUS. Mr. Tam was also appointed to the Board of Directors.
"Peter's promotion to president, and appointment to the VIVUS board of directors, acknowledges his outstanding leadership qualities, vast experience and passionate commitment to VIVUS' mission to develop and deliver truly innovative therapies for large markets," stated Mr. Wilson. "Throughout his 16-year tenure at VIVUS, Peter has made major contributions to the company, including the early work that served as the foundation for the in-licensing and development of Qnexa, business development activities that led to the successful partnering/out-licensing of Evamist and the overall development strategy for avanafil. He clearly has the strategic vision, leadership skills, and operational effectiveness to create value for VIVUS and its shareholders at this critical juncture for the company. We are pleased to promote Peter to president of VIVUS."
Mr. Tam has held various leadership positions at VIVUS over the last 16 years, including director of clinical and corporate development, senior vice president of product and corporate development and chief operating officer. His responsibilities have included clinical development, strategic planning, and corporate/business development. Prior to VIVUS, Mr. Tam held various research and clinical development positions at Gen
|SOURCE VIVUS, Inc.|
Copyright©2009 PR Newswire.
All rights reserved